Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP).
about
Contemporary management of primary immune thrombocytopenia in adultsRomiplostim in children with chronic refractory ITP: randomized placebo controlled study.The development of romiplostim for patients with immune thrombocytopenia.Immune thrombocytopenia: no longer 'idiopathic'.Management of immune thrombocytopenic purpura in children: potential role of novel agents.Romiplostim: a review of its use in immune thrombocytopenia.Romiplostim for the treatment of primary immune thrombocytopenia.Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.Patients with ≥ 20 × 10(9)/l platelets at baseline may have a prompt response to romiplostim during the early phase of treatment: an italian single-institution experience.Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency.Romiplostim in the management of thrombocytopenia in a patient with autoimmune hepatitis.Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.Positioning new treatments in the management of immune thrombocytopeniaSplenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim.Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.Thrombopoietin receptor agonists in primary immune thrombocytopenia.Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).Romiplostim as a treatment for immune thrombocytopenia: a review.Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®.Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia.Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis.Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain.Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia.Clinical Practice Updates in the Management Of Immune Thrombocytopenia.Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
P2860
Q26853680-454431C4-EAB1-45B2-A8F8-673DEF09A91AQ33394122-AB9BED33-6821-45B9-A143-AEA10651B009Q33394636-A13FA537-2216-48ED-A48E-22BA9464EEACQ33395624-E88C74FB-BF3A-4E37-B45F-BE639790E8A5Q33395863-A74189B9-B81F-40E5-BB98-27EAC60FEE90Q33399598-533F4DE2-98DA-4634-BEEC-A2ED35D7BDABQ33400560-CB9631DE-673F-4385-B621-B5073877AACEQ33401083-27627E88-7D89-4FD6-9A35-E4370AD2153FQ33401956-F06B11D9-EEA7-40ED-8C3A-0A8D0B81B8C2Q33402430-46CAA4D2-1F43-44D8-B201-336866BD041AQ33402505-D4D7A588-AD9B-417B-8763-D3E461961530Q33402513-42803AFD-38E1-4B46-AC34-E478AE4CC20DQ33402591-F3F138BE-E350-4320-A2EB-F695BD737498Q33404095-8C4804B7-E618-40FB-A2FF-BB36CB7921FCQ33404320-240237BA-91DC-4EF6-95D6-6E5DF76E85C3Q33406032-62A9D1BE-5229-4F34-BC47-DD25B6692AE5Q33406166-AEB36BD4-9BC8-452A-B31A-7D903E2F2E1AQ33406819-55A2E3E3-A797-4DB2-8101-FABCCB115C2FQ33407110-6EED74BA-73F9-4DDA-BFB7-3EDA7C3CD5D2Q33407623-496B830C-C90E-4F86-95B4-B6357526D176Q33409611-EDB8A371-2D10-4260-AC5E-BC420218E5A9Q33418391-D398B9DF-0B74-403A-AC31-E9C92315F45BQ33420059-DF874826-8F12-4A83-B201-A3B9DEF74AF8Q33424664-BBA8FD0F-CD24-47C2-BBA2-DBD764E1DF4AQ33425628-F8C42A6D-8D53-4138-9234-1168EF4E1F2AQ33435986-0EF78315-3920-4525-84D9-7B9449D498F3Q33437732-F5EBE9F7-EBB7-4AF8-A77B-CE611065ABA6Q33443533-A822226D-0F2F-4CBD-9565-A8CB10D23491Q44713760-6A679CAC-D120-46CB-9F46-DD6A3BA9D4B2Q46047574-CE34DFAC-56CC-4C8A-BC2A-143D95A3D8F7Q47161464-731D457C-B06F-431D-8965-1A377F876B36Q47213468-A10B0541-BC3D-46D5-BD30-E887B047090D
P2860
Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP).
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluation of bleeding and thr ...... immune thrombocytopenia (ITP).
@ast
Evaluation of bleeding and thr ...... immune thrombocytopenia (ITP).
@en
type
label
Evaluation of bleeding and thr ...... immune thrombocytopenia (ITP).
@ast
Evaluation of bleeding and thr ...... immune thrombocytopenia (ITP).
@en
prefLabel
Evaluation of bleeding and thr ...... immune thrombocytopenia (ITP).
@ast
Evaluation of bleeding and thr ...... immune thrombocytopenia (ITP).
@en
P2093
P1476
Evaluation of bleeding and thr ...... immune thrombocytopenia (ITP).
@en
P2093
D Matthew Guo
J L Nichol
J N George
L M Aledort
M D Tarantino
T B Gernsheimer
P304
P356
10.1111/J.1538-7836.2010.03830.X
P577
2010-03-03T00:00:00Z